Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000727 · ClinicalTrials.gov registry record · Phase 3
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 13,026
- Enrollment target
NCT01000727 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 13,026 participants.
The verdict
NCT01000727, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13,026 participants
- Enrollment target
Study Summary
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).
Interventions
- DRUG Placebo
- OTHER Standard Therapy
- DRUG Darapladib 160 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,026 participants |
| Start Date | 2009-12-01 |
| Est. Completion | 2014-04-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01000727
The ClinicalTrials.gov registry entry for NCT01000727 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 13,026 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01000727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01000727 about?
NCT01000727 is a clinical study titled "The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial". This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 3...
What is the current status of trial NCT01000727?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13,026 participants. The study started on 2009-12-01. Estimated completion is 2014-04-24.
What interventions are being tested in trial NCT01000727?
The interventions under investigation include: Placebo (DRUG), Standard Therapy (OTHER), Darapladib 160 mg (DRUG).
Who is sponsoring clinical trial NCT01000727?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.